Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Yantai Dongcheng Acquires China Ops of Global Medical Solutions for $70 Million

publication date: Mar 28, 2016
Yantai Dongcheng Biochemicals paid $69.8 million to acquire the China assets of Global Medical Solutions, a US company that makes nuclear medicine and imaging contrast products. GMS, which operates mainly in Asia Pacific, described the transaction as a strategic partnership that will be positive for GMS in the long term. In addition, GMS said it would continue to operate in China even though the sale included all of its current China operations. GMS did not specify any details about the synergism it expects between itself and Dongcheng. More details....

Stock Symbol: (SHZ: 002675)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital